Temozolomide promotes genomic and phenotypic changes in glioblastoma cells

BACKGROUND: Temozolomide (TMZ) is a first-line drug for the treatment of glioblastoma. Long-term TMZ-treated tumour cells acquire TMZ resistance by profound reprogramming of the transcriptome, proteome, kinome, metabolism, and demonstrate versatile and opposite changes in proliferation, invasion, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Stepanenko, Aleksei A., Andreieva, Svitlana V., Korets, Kateryna V., Mykytenko, Dmytro O., Baklaushev, Vladimir P., Huleyuk, Nataliya L., Kovalova, Oksana A., Kotsarenko, Kateryna V., Chekhonin, Vladimir P., Vassetzky, Yegor S., Avdieiev, Stanislav S., Dmitrenko, Vladimir V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858898/
https://www.ncbi.nlm.nih.gov/pubmed/27158244
http://dx.doi.org/10.1186/s12935-016-0311-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858898/
https://www.ncbi.nlm.nih.gov/pubmed/27158244
http://dx.doi.org/10.1186/s12935-016-0311-8

Ejemplares similares